A. Moffa, Eugenio de Corso, Domiziana Nardelli, A. Loperfido, J. Galli, Peter M. Baptista, Manuele Casale
tlooto Summary
Tezepelumab improves CRSwNP symptoms and polyp burden and lowers systemic corticosteroid and surgical needs and targets upstream inflammation, including T2 and non-T2 types.
Abstract
Highlights • Tezepelumab improves CRSwNP symptoms and polyp burden.• Tezepelumab reduces nasal congestion and loss of smell in CRSwNP.• Tezepelumab is effective in patients with CRSwNP and comorbid asthma.• Tezepelumab lowers systemic corticosteroid and surgical needs.• Tezepelumab targets upstream inflammation, including T2 and non-T2 types.
Citation format
MOFFA, A., et al. The emerging role of anti-thymic stromal lymphopoietin monoclonal antibody (tezepelumab) in comorbid and non-comorbid crswnp patients: A scoping review. Brazilian Journal of Otorhinolaryngology, 2026, 92(2): 101768.